Breaking AI & Tech News Analyzed

The Lead Doctors, scientists, and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference. Breakthroughs in Cancer Treatment The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year's theme, “the science and practice of translation: improving cancer outcomes worldwide”. Smart Drugs in Cancer Treatment Researchers have developed a smart drug that stops cancer cells hiding. The experimental tablet, GRWD5769, can help shrink tumours by at least 30% in six of the world’s most common forms of the disease, delegates in Chicago were told. 26 of 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers who were given GRWD5769 alongside cemiplimab had tumour reductions of at least 30%. 15 had tumour reductions of at least 30%. A Daily Pill for Pancreatic Cancer A pill that doubles survival time in patients with pancreatic cancer was presented at the conference. In a trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill, daraxonrasib, doubled survival time, with fewer side-effects compared with chemotherapy. Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy. Safely Skipping Some Treatments Some patients can safely skip some treatments, according to research presented at the conference. A genomic test could pave the way for a new era of personalised medicine, enabling doctors to determine which patients can safely skip chemotherapy. The Optima trial, led by University College London, followed 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. Those with a low score on the genomic test could be treated safely with hormone therapy alone. The Future of Cancer Treatment Urgent action is required to cope with rising cancer cases. The world faces a cancer workforce crisis, experts said, with a shortage of 100 million staff expected by 2050 when 100,000 people will be being diagnosed every day. A 21% increase in cancer incidence is predicted, according to a report presented at the conference. The rate is set to rise from 165 per 100,000 people in 2025 to 200 per 100,000 in 2050.

The Bridge Between Art and ScienceWhy do we find things beautiful? More precisely, why do some paintings of coloured dots in rippling patterns inspire in me something like revelation? The idea that beauty is the feeling you get when encountering truth is unfashionable in the arts, but lingers in the sciences. The physicist Paul Dirac once proposed that it is more important that a formula is beautiful than that it can be proven: when a perfectly beautiful theory produces results that cannot be real, he argued, then we should not discard the theory but reconsider what is real.Since the 1970s, Terry Winters has been rebuilding that bridge between art and science. Taking inspiration from disciplines including botany – his early paintings, particularly, evoke sprouting pods and tangled roots – engineering, computer modelling and cybernetics, his paintings might be understood as diagrammatic approximations of the patterns that govern everything from the division of cells to the constellation of stars. If every era has to renew its standards of beauty to reflect new understandings of how the world is constructed, then Winters comes as close to providing that model as any living painter.Mathematical Patterns in Visual ArtThese eight new works take their titles from the language of geometry and mathematics: Area, Array, Field, Locus, Point, Scope, Sequence and Set. Each is composed of overlapping patterns that pull each other out of shape according to invisible laws of attraction and repulsion. Field is indicative: on a sooty pink ground, a dense grid of dusty blue cells bends inwards like a trampoline beneath a bowling ball, while an intersecting arrangement of larger circles swells outwards. The disorienting effect of this push-pull is exaggerated by an optical illusion, created by ragged phosphorescent orange haloes around the blue circles, that makes them appear to be craters sunk into the crust of paint. You have to walk up to the surface to be reassured that it is flat.Point shows a teeming landscape of cells bulging outwards at the centre, as if a scum of frogspawn had been skimmed off a pond and placed under a paperweight microscope. In Sequence, a storm of pink interference skims through a yellow circle split like a brain into hemispheres, while a nebulous weather system sweeps in from the right. In Scope, vaguely symbolic arrangements of freshwater blue and desert orange nodules move across the familiar circle-within-a-square geometry of Leonardo's Vitruvian Man. Where that famous demonstration of sacred geometries exudes stillness and calm, the systems that run through Winters' worlds are wild and strange. Here, as much importance is given to the subjective factors of perception and consciousness as the objective principles of logic and proportion.Optical Illusions and Sensory ExperienceAll of this should not distract from the pure sensory pleasure afforded by these pictures. In Locus, another optical illusion seems to lift the red edge of the painting off the canvas like a clumsy wooden frame, squeezing the pockmarked sphere at its centre so that it balloons outwards, threatening to burst. The same cadmium red, so sandy that the pigment seems barely to have been suspended in oil, turns carmine pockets into rock formations that climb off the surface of Set. These sleights of hand evoke the more secular movement of op art, in which patterns are manipulated to exploit the idiosyncrasies of human perception rather than to uncover deeper truths. Which begs the question: is this all just a conjuring trick?Rediscovering the Renaissance ApproachThere is something magical about these works. Even though Winters is generally credited with having extended the lineage of modernist American painting into the present, his practice is in this sense pre-modern. In its rejection of the idea that art should be separated from science, it resembles the Renaissance attitude according to which painting is no less a tool for understanding the world than mathematics, and magic is just the name for things we don't yet understand. His commitment to synthesising diverse spheres of knowledge, his alchemist's commitment to materials, and his sheer technical ability certainly mark him out in a scene recently overwhelmed by chancers and charlatans, bandwagoners and snake-oil salesmen. That his work is enjoying a revival might be taken as an encouraging sign.Beauty as a Path to TruthDirac, incidentally, was proved right. He formulated a theory that was so beautiful it couldn't possibly be wrong, even though it implied the existence of phenomena that everyone agreed must be impossible. He stood by it, and a few years later, someone else discovered anti-matter. Winters' paintings likewise offer a flash of those secret patterns that underpin the physical world, and which science has yet to illuminate. Which is to say, they're beautiful.Exhibition DetailsTerry Winters: Along the River is at Modern Art, London, until 11 July

The Rise of Marco da Silva Ferreira Last year, for dance's answer to the Turner prize, the Rose international dance prize, four choreographers competed for £40,000. One of those finalists was the Portuguese choreographer Marco da Silva Ferreira. He didn't win, but he definitely marked himself out as an of-the-moment voice. The Event Details: A Dance of Protest and Partying Da Silva Ferreira's dance is like minimalist music: small cells of movement, repeated, gradually shift and morph. A slinking step, a strut, the pop of a muscular torso, a slippery moonwalk, etc, etc. Eight dancers are in unison, but there's no sense of them being automatons – they're real, sweaty humans in shiny trousers and chainmail vests with red makeup smeared under their eyes. The Data Analysis: A Slow Build of Energy This piece, F*cking Future, is all about the slow build. The kind that might seem boring till you tune in and live it with them, beat by beat. It's the opposite of the show-us-everything-you-can-do school of dance: it's anti-instant gratification, no quick dopamine hit. The Impact Analysis: A Politics of Resistance You think – or I thought – that we're heading for an amazing climax: finally the dam will break, the banks will burst, the beat will drop. You can see the style and verve of these dancers, not least Da Silva Ferreira himself, bursting against the confinement of the work's structure. This will be one hell of a catharsis. The Prediction: A Lasting Impression Except that never quite happens. The momentum absorbs back into the group. Is this the politics of resistance at play? Not giving us the easy out, bowing to the harmony of the group. One way a choreographer can work is much like a DJ – rather than just being about shaping dancers' movements, it's about shaping the energy in the room across the course of an hour or so, through bodies, sound, light and motion.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."

The Alarming Reality of Prison Overcrowding in Europe Belgium, one of Europe's richest countries, is grappling with a deepening prison overcrowding crisis. The country's 39 prisons are currently housing 13,733 inmates, significantly exceeding their capacity of 11,064. This has resulted in inhumane conditions, with prisoners often confined to small cells for 22 to 23 hours a day. The Human Cost of Overcrowding The crisis has led to a surge in health issues, including scabies, bed bugs, and monkeypox, as well as increased violence and suicidal ideation among prisoners. The situation is further exacerbated by staff shortages, with guards facing severe exhaustion and burnout. The Data Behind the Crisis In mid-May, 754 detainees were sleeping on mattresses on the floor, up from 672 in December. Belgium's prison population has increased dramatically since the COVID-19 pandemic. Occupancy rates are highest in Cyprus, followed by Slovenia, France, Croatia, Italy, Romania, Austria, and Belgium. The Impact on Society The prison overcrowding crisis has significant implications for society, including increased recidivism rates and a lack of rehabilitation opportunities. Critics are calling for a greater emphasis on societal reintegration rather than just security, through alternative punishment and rehabilitation programs. The Way Forward To address the crisis, experts recommend that governments prioritize rehabilitation and reintegration programs, as well as explore alternative sentencing options. Additionally, there is a need for increased investment in prison infrastructure and staff training to ensure that prisoners receive adequate care and support.

The Urgent Wake-Up Call for Women's HealthcareBBC presenter Emma Barnett delivers a powerful and unflinching look at the realities of living with endometriosis in her new documentary, Fighting Endometriosis. The program moves beyond a mere medical overview, serving as a stark indictment of a healthcare system that routinely minimizes women's pain and underfunds critical research into debilitating conditions.Unmasking the Agony of a Hidden EpidemicThe documentary details the severe physical toll of the condition, where cells resembling the uterine lining grow elsewhere in the body, causing debilitating pain. Barnett highlights the inadequate treatment options currently available, which are largely limited to hormonal masking or invasive surgeries like hysterectomies. Through candid video diaries and interviews with other sufferers—such as a 26-year-old named Chloe who was forced to seek surgery abroad—Barnett exposes the daily struggle that belies her professional success.The £12.5 Billion Economic Toll of Medical MisogynyA critical revelation in the documentary is the staggering economic impact of the disease. While endometriosis is often deprioritized in research funding because it is not directly fatal, it costs the UK economy £12.5bn annually due to women being forced out of the workforce. Furthermore, the data reveals a systemic failure in diagnosis and care:1 in 10 women of reproductive age in the UK are affected by the condition.It takes an average of 9 years to receive a proper diagnosis in the UK.Sufferers are frequently misdiagnosed with conditions like appendicitis, IBS, or PMS.Confronting Politicians on Systemic Healthcare FailuresBarnett refuses to accept the status quo, directly confronting political figures like former Health Secretary Wes Streeting about the medical misogyny deeply rooted in society. The documentary argues that the minimization of women's pain—often dismissed by medical professionals due to its supposedly subjective nature—is no longer an acceptable excuse. By bringing these hidden struggles into the public eye, the film forces a conversation about accountability and the urgent need to reevaluate how female health issues are prioritized by policymakers.The Future of Endometriosis Research and AdvocacyWhile the documentary does not end on an overly optimistic note—acknowledging that millions remain in daily agony—it marks a crucial step forward in health advocacy. As high-profile figures like Barnett and Lena Dunham continue to articulate the severe realities of the condition, the medical establishment will face increasing pressure to innovate. The hope is that highlighting both the massive economic cost and the profound human suffering will finally shift policy priorities, leading to reduced diagnosis times and the development of targeted, curative treatments.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Revolutionary GeneticistCraig Venter, the pioneering geneticist who revolutionized genome sequencing and challenged traditional scientific approaches, has died at age 79. His announcement at the 2001 BioVision conference that humans possess only about 30,000 genes—far fewer than the previously estimated 100,000—shattered scientific assumptions about genetic determinism. "We simply do not have enough genes for this idea of biological determinism to be right," Venter declared, emphasizing that human diversity is shaped primarily by environmental influences rather than hard-wired genetic code.The Breakthrough in Genome SequencingVenter's most significant contribution was developing the revolutionary whole genome shotgun sequencing technique, which allowed for faster, more efficient genome mapping. In 1995, his team achieved the remarkable feat of sequencing the first genome of a living organism, the bacterium Haemophilus influenzae. This breakthrough led to the founding of Celera Genomics in 1998, which aimed to sequence the entire human genome using Venter's innovative methods.The competition between Venter's privately funded Celera and the publicly funded Human Genome Project, spearheaded by the US government and UK's Wellcome Trust, created what scientists described as "testosterone-driven" rivalry. Despite tensions, this competition dramatically accelerated progress in genomics research, culminating in the announcement of the first draft human genome sequence at a White House ceremony in June 2000.The Scientific MaverickVenter was as famous for his bold personality as for his scientific achievements. A brilliant entrepreneur and unapologetic self-promoter, he enjoyed showcasing his success, private plane, yacht, and luxury watches. This flamboyant approach made him both admired and controversial. James Watson, co-discoverer of DNA's double-helix structure, compared Venter to Hitler for attempting to patent human genes, while others nicknamed him "Darth" Venter after the Star Wars villain.His tendency to break scientific protocols became evident when he revealed that much of the DNA used in Celera's human genome sequencing came from his own cells—a decision that annoyed scientists who felt he had subverted standard processes. "I've been accused of that so many times, I've got over it," Venter responded, noting that the analysis revealed he had an abnormal fat metabolism and elevated risk of Alzheimer's disease.A Life Shaped by Science and WarBorn in Salt Lake City, Utah, Venter had an unconventional path to scientific greatness. Growing up in California, he had a poor academic record and initially pursued "pursuits that involved drink, girls and bodysurfing" rather than education. His life took a dramatic turn during the Vietnam War, where he served as a senior corpsman in a naval hospital's intensive care unit in Da Nang."I witnessed several hundred soldiers die, more often than not while I was massaging their hearts – at times with my bare hand – or attempting to breathe life into them," Venter recalled. "Vietnam would teach me more than I ever wanted to know about the fragility of life." This experience sparked his interest in life sciences, leading him to study at the University of California, San Diego, where he earned a PhD in physiology and pharmacology in 1975.The Legacy of a Scientific PioneerAfter being dismissed as head of Celera in 2002, Venter used his substantial payoff to endow the J. Craig Venter Institute with $100 million. There, he pursued ambitious projects including designing energy-producing microbes and synthesizing bacterial genomes. He later founded Human Longevity and Diploid Genomics, companies that aim to combine artificial intelligence with advances in aging research and gene sequencing to extend human lifespans and improve disease diagnosis.While some of Venter's claims about the primacy of environmental influences over genetics have been questioned, his impact on genomics research remains undeniable. His revolutionary sequencing techniques transformed the field, and his competitive approach accelerated what would have otherwise been a much slower process of mapping the human genome. As the scientific community remembers Craig Venter, it acknowledges a complex figure who was simultaneously a brilliant innovator, a controversial competitor, and a transformative force in our understanding of life's fundamental building blocks.